SAN MATEO, Calif.--(BUSINESS WIRE)--Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended June 30, 2011. Revenues: The Company’s consolidated revenues for the three months ended June 30, 2011 totaled $0.178 million. The revenues in the second quarter were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company’s DeltaOneTM program.
